Macrolides in dermatology

Clinics in Dermatology

Volumn 21, Issue 1, 2003, Pages 40-49

  Scheinfeld, Noah S ^a   Tutrone, William D ^a   Torres, Omar ^a   Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CEFACLOR; CEFADROXIL; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN A; DICLOXACILLIN; DIGOXIN; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; FLURITHROMYCIN; MACROLIDE; METHYLPREDNISOLONE; MINOCYCLINE; PHENYTOIN; ROXITHROMYCIN; SIMVASTATIN; TELITHROMYCIN; TERFENADINE; TETRACYCLINE; THEOPHYLLINE; WARFARIN;

ACNE; ALLERGIC REACTION; ANTHRAX; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIOSTASIS; BIOAVAILABILITY; BLOOD BRAIN BARRIER; BOUTONNEUSE FEVER; BRUCELLOSIS; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG ADSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STABILITY; ERYSIPELAS; ERYTHEMA; GRANULOMA INGUINALE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; IRRITANT DERMATITIS; LYME DISEASE; LYMPHOGRANULOMA VENEREUM; NAUSEA; NEUTROPHIL CHEMOTAXIS; PAIN; PAPILLOMATOSIS; PERIORAL DERMATITIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; PRURITUS; PYODERMA; RESPIRATORY TRACT INFECTION; ROSACEA; SKIN ABSCESS; SKIN INFECTION; SKIN INJURY; SKIN ULCER; SOFT TISSUE INFECTION; STOMACH ULCER; TREATMENT FAILURE; ULCUS MOLLE; VOMITING; WOUND INFECTION; XEROSIS;

EID: 0037217020     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00323-1     Document Type: Article

References (122)

1. McGuire J.M., Bunch R.L., Anderson R.C., et al. Ilolycin, a new antibiotic. Antibiot Chemother. 2:1952;281-283.
2. Washington J.E., Wilson W.R. Erythromycin a microbiological and clinical perspective after 30 years of clinical use . Mayo Clin Proc. 60:1985;189-203.
3. Malamborg A.S. The renaissance of erythromycin. J Antimicrob Chemother. 18:1986;293-295.
4. Kirst H.A. Semi-synthetic derivatives of erythromycin. Prog Med Chem. 30:1993;57-88.
5. Matsuoka N., Eguchi K., Kawakami A., et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol. 104:1996;501-508.
6. Fujita K., Shimizu T., Majima Y., Sakakura Y. Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur Arch Otorhinolaryngol. 257:2000;199-204.
7. Woo P.C., Chow L.W., Ma E.S., Yuen K.Y. Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. Pharmacol Res. 39:1999;49-54.
8. Schlossberg D. Azithromycin and clarithromycin. Med Clin North Am. 79:1995;803-815.
9. Depoortere I. Motilin and motilin receptors characterization and functional significance . Verh K Acad Geneeskd Belg. 63:2001;511-529.
10. Yatsunami J., Hayashi S. Fourteen-membered ring macrolides as anti-angiogenic compounds. Anticancer Res. 21:2001;4253-4258.
11. Matsuura B., Dong M., Miller L.J. Differential determinants for peptide and non-peptidyl ligand binding to the motilin receptor. Critical role of second extracellular loop for peptide binding and action. J Biol Chem. 277:2002;9834-9839.
12. Hoppe J.E. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. Pediatr Infect Dis J. 11:1992;189-193.
13. Mather L.E., Austin K.L., Philpot C.R., McDonald P.J. Absorption and bioavailability of oral erythromycin. Br J Clin Pharmacol. 12:1981;131-140.
14. Fraschini F., Scaglione F., Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet. 25:1993;189-204.
15. Sadick N.S. Systemic antibacterial agents. Wolvertron S.E. Comprehensive dermatologic drug therapy. 2001;36 W. B. Saunders Company, Philadelphia.
16. Epstein M.E., Amodio-Groton M., Sadick N.S. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol. 37:1997;365-381.
17. Brogden R.N., Peters D.H. Dirithromycin a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy . Drugs. 48:1994;599-616.
18. Lassus A. Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother. 25:(Suppl A):1990;115-121.
19. Amaya-Tapia G., Aguirre-Avalos G., Andrade-Villanueva J., et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J Antimicrob Chemother. 31:(Suppl E):1993;129-135.
20. Langtry H.D., Balfour J.A. Azithromycin. A review of its use in paediatric infectious diseases. Drugs. 56:1998;273-297.
21. Treadway G., Reisman A. Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. Int J Antimicrob Agents. 18:2001;427-431.
22. Fernandez-Obregon A.C. Azithromycin for the treatment of acne. Int J Dermatol. 39:2000;45-50.
23. Gruber F., Grubisic-Greblo H., Kastelan M., et al. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa. J Chemother. 10:1998;469-473.
24. Parsad D., Pandhi R., Nagpal R., Negi K.S. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol. 28:2001;1-4.
25. Elewski B.E. A novel treatment for acne vulgaris and rosacea. J Eur Acad Dermatol Venereol. 14:2000;423-424.
26. Bowden F.J., Savage J. Donovanosis treatment with azithromycin . Int J STD AIDS. 9:1998;61-62.
27. Woodward C., Fisher M.A. Drug treatment of common STDs Part I. Herpes, syphilis, urethritis, chlamydia and gonorrhea . Am Fam Phys. 60:1999;1387-1394.
28. Martin D.H., Sargent S.J., Wendel G.D. Jr, et al. Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin Infect Dis. 21:1995;409-414.
29. Bass J.W., Freitas B.C., Freitas A.D., et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J. 17:1998;447-452.
30. Cascio A., Colomba C., Antinori S., et al. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children a randomized controlled trial . Clin Infect Dis. 15:2002;34.:154-8.
31. Citterio F., Di Pinto A., Borzi M.T., et al. Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. Transplant Proc. 33:2001;2134-2135.
32. Nash M.M., Zaltzman J.S. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. Transplantation. 65:1998;1611-1615.
33. Gruber F., Zamolo G., Saftic M., et al. Treatment of confluent and reticulated papillomatosis with azithromycin. Clin Exp Dermatol. 23:1998;191.
34. Weigl L.B., Beham A., Schnopp C., et al. Confluent and reticulate papillomatosis. Successful therapy with azithromycin. Hautarzt. 52:2001;947-949.
35. Raja Babu K.K., Snehal S., Sudha Vani D. Confluent and reticulate papillomatosis successful treatment with azithromycin . Br J Dermatol. 142:2000;1252-1253.
36. Luft B.J., Dattwyler R.J., Johnson R.C., et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 124:1996;785-791.
37. Strle F., Maraspin V., Lotric-Furlan S., et al. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. Infection. 24:1996;64-68.
38. Solera J., Beato J.L., Martinez-Alfaro E., et al. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis. 32:2001;506-509.
39. Duran J.M., Amsden G.W. Azithromycin indications for the future? Expert Opin Pharmacother. 1:2000;489-505.
40. Maskell J.P., Sefton A.M., Williams J.D. Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes. J Antimicrob Chemother. 25:(Suppl A):1990;19-24.
41. Kitzis M.D., Goldstein F.W., Miegi M., et al. In vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother. 25:(Suppl A):1990;15-18.
42. Goldstein E.J., Citron D.M., Hunt Gerardo S., et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. Antimicrob Agents Chemother. 42:1998;1127-1132.
43. Retsema J., Girard A., Schelkly W., et al. Spectrum and mode of action of azithromycin (CP-662, 993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 31:1987;1939-1947.
44. Slaney L., Chubb H., Ronald A., et al. In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis. J Antimicrob Chemother. 25:(Suppl A):1990;1-5.
45. Lode H., Borner K., Koeppe P., et al. Azithromycin - review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother. 37:(Suppl C):1996;1-8.
46. Sturgill M.G., Rapp R.P. Clarithromycin a review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles . Ann Pharmacother. 26:1992;1099-1108.
47. Northcutt VJ, Craft JC, Pichotta P. Safety and efficacy of clarithromycin (C) compared to erythromycin (E) in the treatment (tx) of bacterial skin or skin structure infections (SSSIs) [abstract 1339]. In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta 1990.
48. Parish L.C. Clarithromycin in the treatment of skin and skin structure infections two multicenter clinical studies . Int J Dermatol. 32:1993;528-532.
49. Franck N., Cabie A., Villetter B., et al. Treatment of Mycobacterium chelonae induced skin infection with clarithromycin. J Am Acad Dermatol. 28:1993;1019-1020.
50. Wharton J.R., Wilson P.L., Kincannon J.M. Erythrasma treated with single-dose clarithromycin. Arch Dermatol. 134:1998;671-672.
51. Torresani C. Clarithromycin a new perspective in rosacea treatment . Int J Dermatol. 37:1998;347-349.
52. Torresani C., Pavesi A., Manara G.C. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 36:1997;942-946.
53. Yazawa N., Ihn H., Yamane K., et al. The successful treatment of prurigo pigmentosa with macrolide antibiotics. Dermatology. 202:2001;67-69.
54. Jang H.S., Oh C.K., Cha J.H., et al. Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics. J Am Acad Dermatol. 44:2001;652-655.
55. Hardy D.J., Swanson R.N., Rode R.A., et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 34:1990;1407-1413.
56. Barry A.L., Jones R.N., Thornsberry C. In vitro activities of azithromycin (CP62, 993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clindamycin. Antimicrob Agents Chemother. 32:1988;752-754.
57. Waites K.B., Cassell G.H., Canupp K.C., et al. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother. 32:1988;1500-1502.
58. Bowie W.R., Shaw C.E., Chan G.W., et al. In vitro activity of RO 15-8074, RO 19-5247, A56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother. 31:1987;470-472.
59. Alvarez-Elcoro S., Enzler M.J. The macrolides erythromycin, clarithromycin, and azithromycin . Mayo Clin Proc. 74:1999;613-634.
60. Guay D.R. Macrolide antibiotics in paediatric infectious diseases. Drugs. 51:1996;515-536.
61. Gammon W.R., Meyer C., Lantis S., et al. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol. 14:1986;183-186.
62. Eady E.a, Cove J.H., Holland K.T., Cunliffe W.J. Erythromycin resistant propionibacteria in antibiotic treated acne patients association with therapeutic failure . Br J Dermatol. 121:1989;51-57.
63. Rothman K.f, Pochi P.E. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol. 19:1988;431-442.
64. Sharma P.K., Yadav T.P., Gautam R.K., et al. Erythromycin in pityriasis rosea a double-blind, placebo-controlled clinical trial . J Am Acad Dermatol. 42:2000;241-244.
65. Bigby M. A remarkable result of a double-masked, placebo-controlled trial of erythromycin in the treatment of pityriasis rosea. Arch Dermatol. 136:2000;775-776.
66. Martin J.M., Green M., Barbadora K.A., Ward E.R. Erythromycin-resistant group A streptococci in school children in Pittsburgh. N Engl J Med. 346:2002;1200-1206.
67. Puhvel S.M. Effects of treatment with erythromycin 1.5 percent topical solution or clindamycin phosphate 1.0 percent topical solution on P. acnes counts and free fatty acid levels. Cutis. 31:1983;339-342.
68. Eady E.A. Bacterial resistance in acne. Dermatology. 196:1998;59-66.
69. Dobson R.L., Belknap B.S. Topical erythromycin solution in acne. Results of a multiclinic trial. J Am Acad Dermatol. 3:1980;478-482.
70. Rapaport M., Puhvel S.M., Reisner R.M. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis. 30:1982;122-126., 130, 132-5.
71. Lesher J.L. Jr, Chalker D.K., Smith J.G. Jr, et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol. 12:1985;526-531.
72. Strauss J.S., Stranieri A.M. Acne treatment with topical erythromycin and zinc effect of Propionibacterium acnes and free fatty acid composition . J Am Acad Dermatol. 11:1984;86-89.
73. Jones E.L., Crumley A.F. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol. 117:1981;551-553.
74. Valsecchi R., Pansera B., Reseghetti A. Contact allergy to erythromycin. Contact Dermatitis. 34:1996;428.
75. Martins C., Freitas J.D., Goncalo M., Goncalo S. Allergic contact dermatitis from erythromycin. Contact Dermatitis. 33:1995;360.
76. Fernandez Redondo V., Casas L., Taboada M., Toribio J. Systemic contact dermatitis from erythromycin. Contact Dermatitis. 30:1994;311.
77. Fernandez Redondo V., Casas L., Taboada M., Toribio J. Systemic contact dermatitis from erythromycin. Contact Dermatitis. 30:1994;43-44.
78. Wintermeyer S.M., Abdel-Rahman S.M., Nahata M.C. Dirithromycin a new macrolide . Ann Pharmacother. 30:1996;1141-1149.
79. Deiriennic M., Escande J.P. Dirithromycin in the treatment of skin and skin structure infections. J Antimicrob Chemother. 31:(Suppl C):1993;159-168.
80. Dilorenzo P, Shupbach C, Salisbury J Dirithromycin (D) 5 days versus erythromycin base (E) 7 days in skin and soft tissue infections (abstract 402). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993:192.
81. Wasilewski M.M., Wilson M.G., Sides G.D., Stotka J.L. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. J Antimicrob Chemother. 46:2000;255-262.
82. Murray L, Kelly GL. Physicians Desk Reference 2001, 55th edition. Montvale, NJ: Medical Economics, 2001: 402-411, 439-449, 2106-2109, 2546-2553.
83. Stewart A.K., Trudel S., Al-Berouti B.M., et al. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood. 15:1999;4441. 93.
84. Morris T.C., Ranaghan L., Morrison J. Phase II trial of clarithromycin and pamidronate therapy in myeloma. Med Oncol. 18:2001;79-84.
85. Moreau P., Huynh A., Facon T., et al. Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Francais du Myelome (IFM) Leukemia. 13:1999;490-491.
86. Guerin J.M., Leibinger F. Why not to use erythromycin in GI motility. Chest. 121:2002;301-302.
87. Ohwada S., Satoh Y., Kawate S., et al. Low-dose erythromycin reduces delayed gastric emptying and improves gastric motility after Billroth I pylorus-preserving pancreaticoduodenectomy. Ann Surg. 234:2001;668-674.
88. Hirschmann J.V. Overview of antibiotics. Freedberg I.M., Eisen A.Z., Wolff K., et al. Fitzpatrick's dermatology in general medicine. 5th ed:1999;2834-2835 McGraw-Hill, New York.
89. Longo G., Valenti C., Gandini G., et al. Azithromycin-induced intrahepatic cholestasis. Am J Med. 102:1997;217-218.
90. Cascaval R.I., Lancaster D.J. Hypersensitivity syndrome associated with azithromycin. Am J Med. 110:2001;330-331.
91. Trevisi P., Patrizi A., Neri I., Farina P. Toxic pustuloderma associated with azithromycin. Clin Exp Dermatol. 19:1994;280-281.
92. Wallace M.R., Miller L.K., Nguyen M.T., Shields A.R. Ototoxicity with azithromycin. Lancet. 343:1994;241.
93. Ress B.D., Gross E.M. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol. 109:2000;435-437.
94. Schmutz J.L., Barbaud A., Trechot P. Skin eruptions due to azithromycin (Azadose-Zithromax) and infectious mononucleosis. Ann Dermatol Venereol. 128:2001;579.
95. Schissel D.J., Singer D., David-Bajar K. Azithromycin eruption in infectious mononucleosis a proposed mechanism of interaction . Cutis. 65:2000;163-166.
96. Milkovic-Kraus S., Kanceljak-Macan B. Occupational airborne allergic contact dermatitis from azithromycin. Contact Dermatitis. 45:2001;184.
97. Gangemi S., Ricciardi L., Fedele R., et al. Immediate reaction to clarithromycin. Allergol Immunopathol (Madr). 29:2001;31-32.
98. Hamamoto Y., Ohmura A., Kinoshita E., Muto M. Fixed drug eruption due to clarithromycin. Clin Exp Dermatol. 26:2001;48-49.
99. Vangala R., Cernek P.K. Hypersensitivity reaction to clarithromycin. Ann Pharmacother. 30:1996;300.
100. Gavura S.R., Nusinowitz S. Leukocytoclastic vasculitis associated with clarithromycin. Ann Pharmacother. 32:1998;543-545.
101. Abouesh A., Hobbs W.R. Clarithromycin-induced mania. Am J Psychiatry. 155:1998;1626.
102. Sides G.D., Conforti P.M. Safety profile of dirithromycin. J Antimicrob Chemother. 31:(Suppl C):1992;175-185.
103. Jacobson K. Clinical efficacy of dirithromycin in pneumonia. J Antimicrob Chemother. 31:(Suppl C):1993;121-129.
104. Peters D.H., Clissold P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 44:1992;117-164.
105. Vance E., Watson-Bitar M., Gustovson L., et al. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother. 39:1995;1355-1360.
106. Gillum TG, Bruzzese VC, Israel DS Effect of multiple oral doses of clarithromycin (clary) on the pharmacokinetics of 2′-3′-dideoxyinosine (ddI) in patients infected with HIV [abstract]. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington, DC. 1993.
107. Datri 001 Study Group. Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis evidence of drug interaction [abstract]. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington, DC. 1993.
108. Amsden G.W., Cheng K.L., Peloquin C.A., Nafziger A.n. Oral cimetidine prolongs clarithromycin absorption. Antimicrob Agents Chemother. 42:1998;1578-1580.
109. Spicer S.T., Liddle C., Chapman J.R., et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol. 43:1997;194-196.
110. Lee A.J., Maddix D.S. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 35:2001;26-31.
111. Foster D.R., Milan N.L. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 19:1999;902-908.
112. Foulds G., Hilligoss D.M., Henry E.B., et al. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 31:1991;164-167.
113. Hafner R., Bethel J., Standiford H.C., et al. Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother. 45:2001;1572-1577.
114. Gupta S., Banfield C., Kantesaria B., et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin a randomized, placebo-controlled, parallel-group study . Clin Ther. 23:2001;451-466.
115. McConnell S.A., Nafziger A.N., Amsden G.W. Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers. J Antimicrob Chemother. 43:1999;733-736.
116. Drinkard C.R., Shatin D., Clouse J. Postmarketing surveillance of medications and pregnancy outcomes clarithromycin and birth malformations . Pharmacoepidemiol Drug Safety. 9:2000;549-556.
117. Einarson A., Phillips E., Mawji F., et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol. 15:1998;523-525.
118. Louik C., Werler M.M., Mitchell A.A. Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol. 186:2002;288-290.
119. Jacobson G.F., Autry A.M., Kirby R.S., et al. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol. 184:2001;1352-1354.
120. Goldstein E.J., Citron D.M., Merriam C.V., et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother. 43:1999;2801-2805.
121. Adachi Y., Akamatsu H., Horio T. The effect of antibiotics on the production of superantigen from Staphylococcus aureus isolated from atopic dermatitis. J Dermatol Sci. 28:2002;76-83.
122. Mazzei T., Mini E., Novelli A., et al. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 31:(Suppl C):1993;1-9.